What You Should Know:
– Sheba Medical Center, a leading Israeli hospital renowned for its medical innovation, and its innovation arm, ARC Innovation, have announced a collaborative research agreement with Mana.bio.
– The partnership aims to leverage Mana.bio’s AI-powered programmable RNA delivery platform to overcome technological hurdles in RNA therapeutics, paving the way for enhanced treatments for cancer and autoimmune diseases.
Bridging Technological Gaps in RNA Delivery
The collaboration will focus on utilizing Mana.bio’s AI-based RNA delivery system within Sheba’s advanced research laboratories to target T cells from healthy donors. The study results will then be integrated into Mana.bio’s AI prediction models, further refining and optimizing the RNA delivery mechanism. This process will enhance transfection efficacy and improve safety profiles, leading to more targeted and effective therapies.
Combining Expertise for Enhanced Therapies
Sheba Medical Center will contribute its extensive expertise in T cell-based therapies, while Mana.bio will provide its programmable AI platform for specialized RNA delivery solutions. The joint effort aims to develop a highly efficient system for delivering RNA molecules directly into patients’ T cells, empowering these cells to combat diseases like solid tumors, hematologic cancers, and potentially autoimmune disorders.
Mana.bio’s Programmable RNA Delivery Platform
Mana.bio has emerged as a leader in the rapidly evolving field of RNA delivery technologies. Its AI-powered programmable platform enables the precise and efficient delivery of RNA molecules, offering a promising new approach to treating a wide range of diseases.
“This collaboration signifies the convergence of Sheba’s world-class medical innovation with Mana.bio’s breakthrough AI-based RNA delivery technologies. Together, we are paving the way for the next generation of personalized medicine. By harnessing RNA’s power to reprogram T cells, we have the opportunity to revolutionize treatment for cancer and autoimmune diseases, offering renewed hope to patients worldwide,” said Professor Eyal Zimlichman, MD, Chief Innovation and Transformation Officer at Sheba Medical Center and Founder and Director of ARC Innovation.
